[HTML][HTML] The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases
S Tyagi, P Gupta, AS Saini, C Kaushal… - Journal of advanced …, 2011 - journals.lww.com
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription
factors of nuclear hormone receptor superfamily comprising of the following three subtypes: …
factors of nuclear hormone receptor superfamily comprising of the following three subtypes: …
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
…, V Balasubramanian, T Balganesh, S Tyagi… - Science, 2009 - science.org
New drugs are required to counter the tuberculosis (TB) pandemic. Here, we describe the
synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of …
synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of …
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis
EL Nuermberger, T Yoshimatsu, S Tyagi… - American journal of …, 2004 - atsjournals.org
Tuberculosis continues to be a major cause of morbidity and mortality in the world. The
expansion of tuberculosis control programs has been limited by the lengthy and cumbersome …
expansion of tuberculosis control programs has been limited by the lengthy and cumbersome …
Targeting DnaN for tuberculosis therapy using novel griselimycins
…, M Kurz, C Lair, H Matter, E Nuermberger, S Tyagi… - Science, 2015 - science.org
The discovery of Streptomyces-produced streptomycin founded the age of tuberculosis therapy.
Despite the subsequent development of a curative regimen for this disease, tuberculosis …
Despite the subsequent development of a curative regimen for this disease, tuberculosis …
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative σ factor, SigH
D Kaushal, BG Schroeder, S Tyagi… - Proceedings of the …, 2002 - National Acad Sciences
The pathogenesis of tuberculosis involves multiple phases and is believed to involve both a
carefully deployed series of adaptive bacterial virulence factors and inappropriate host …
carefully deployed series of adaptive bacterial virulence factors and inappropriate host …
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis
S Tyagi, E Nuermberger, T Yoshimatsu… - Antimicrobial agents …, 2005 - Am Soc Microbiol
The nitroimidazopyran PA-824 has potent in vitro activity against Mycobacterium tuberculosis,
a narrow spectrum of activity limited primarily to the M. tuberculosis complex, and no …
a narrow spectrum of activity limited primarily to the M. tuberculosis complex, and no …
[HTML][HTML] Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model
…, M Zhang, KN Williams, CA Peloquin, S Tyagi… - PLoS …, 2007 - journals.plos.org
Background Availability of an ultra-short-course drug regimen capable of curing patients
with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because …
with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because …
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis
EL Nuermberger, T Yoshimatsu, S Tyagi… - American journal of …, 2004 - atsjournals.org
In a recent experimental study using the mouse model of tuberculosis, treatment with a
combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative …
combination of rifampin, moxifloxacin, and pyrazinamide was able to shorten the time to negative …
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis
E Nuermberger, S Tyagi, R Tasneen… - Antimicrobial agents …, 2008 - Am Soc Microbiol
PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report
that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more …
that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more …
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
The novel ATP synthase inhibitor bedaquiline recently received accelerated approval for
treatment of multidrug-resistant tuberculosis and is currently being studied as a component of …
treatment of multidrug-resistant tuberculosis and is currently being studied as a component of …